AMPK-independent Pathways Regulate Skeletal Muscle Fatty Acid Oxidation
Overview
Authors
Affiliations
The activation of AMP-activated protein kinase (AMPK) and phosphorylation/inhibition of acetyl-CoA carboxylase 2 (ACC2) is believed to be the principal pathway regulating fatty acid oxidation. However, during exercise AMPK activity and ACC Ser-221 phosphorylation does not always correlate with rates of fatty acid oxidation. To address this issue we have investigated the requirement for skeletal muscle AMPK in controlling aminoimidazole-4-carboxymide-1-beta-d-ribofuranoside (AICAR) and contraction-stimulated fatty acid oxidation utilizing transgenic mice expressing a muscle-specific kinase dead (KD) AMPK alpha2. In wild-type (WT) mice, AICAR and contraction increased AMPK alpha2 and alpha1 activities, the phosphorylation of ACC2 and rates of fatty acid oxidation while tending to reduce malonyl-CoA levels. Despite no activation of AMPK in KD mice, ACC2 phosphorylation was maintained, malonyl-CoA levels were reduced and rates of fatty acid oxidation were comparable between genotypes. During treadmill exercise both KD and WT mice had similar values of respiratory exchange ratio. These studies suggested the presence of an alternative ACC2 kinase(s). Using a phosphoproteomics-based approach we identified 18 Ser/Thr protein kinases whose phosphorylation was increased by greater than 25% in contracted KD relative to WT muscle. Utilizing bioinformatics we predicted that extracellular regulated protein-serine kinase (ERK1/2), inhibitor of nuclear factor (NF)-kappaB protein-serine kinase beta (IKKbeta) and protein kinase D (PKD) may phosphorylate ACC2 at Ser-221 but during in vitro phosphorylation assays only AMPK phosphorylated ACC2. These data demonstrate that AMPK is not essential for the regulation of fatty acid oxidation by AICAR or muscle contraction.
Loss of protects against MASLD alone or with alcohol intake by preserving lipid homeostasis.
Lamas-Paz A, Hionides-Gutierrez A, Guo F, Jorquera G, Moran-Blanco L, Benede-Ubieto R JHEP Rep. 2024; 7(1):101230.
PMID: 39659733 PMC: 11629569. DOI: 10.1016/j.jhepr.2024.101230.
Pham T, Raun S, Havula E, Henriquez-Olguin C, Rubalcava-Gracia D, Frank E Nat Commun. 2024; 15(1):9826.
PMID: 39537626 PMC: 11561311. DOI: 10.1038/s41467-024-54183-4.
Navigating Preclinical Models and Medications for Peripheral Neuropathy: A Review.
Jali A, Banji D, Banji O, Hurubi K, Tawhari F, Alameer A Pharmaceuticals (Basel). 2024; 17(8).
PMID: 39204115 PMC: 11357099. DOI: 10.3390/ph17081010.
Ammatalli N, Kuricheti S, Veeramachaneni S, Koo Y, Ramanathan G, Yalamanchi A Food Nutr Res. 2024; 68.
PMID: 39113917 PMC: 11305151. DOI: 10.29219/fnr.v68.10745.
AMPK as a mediator of tissue preservation: time for a shift in dogma?.
Langer H, Rohm M, Dasilva Goncalves M, Sylow L Nat Rev Endocrinol. 2024; 20(9):526-540.
PMID: 38760482 DOI: 10.1038/s41574-024-00992-y.